Guest guest Posted November 11, 2008 Report Share Posted November 11, 2008 Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids. http://www.news-medical.net/?id=42667 Alana Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.